J&J to focus on cancer drugs and stop much of its vaccine research

The blood cancer multiple myeloma, where Johnson & Johnson sells the IV treatment Darzalex with Genmab, will be a big focus. 

December 5, 2023 Check out STAT+

Sponsored By

Daniel Hulshizer/AP STAT+ | J&J to emphasize cancer drugs and stop much of its vaccine research The disclosures were made in an interview ahead of an investor meeting that Reed is leading on Tuesday. By Matthew Herper STAT+ | New CAR-T company, Brainchild Bio, will focus first on brain tumors in children Researchers have hit a wall developing cell therapies for children with cancer. A new Seattle startup is trying to fix that. By Jason Mast STAT+ | Cancer drug shortages won't get better under Biden's latest plan President Biden's new plan to curb drug shortages won't help with cancer drug shortages, an administration official confirmed. By John Wilkerson Opinion: A well-meaning FDA policy is a threat to pediatric cancer treatment In an attempt to advance safer, less toxic treatments, the FDA is on the precipice of making a terrible mistake. By E. Anders Kolb

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser